Here’s what you should know:
1. Shire and Takeda are currently developing inflammatory bowel disease treatments. Shire’s compound SHP647 is in phase 3 clinical trials. Takeda has its own IBD drug, Entyvio.
2. Takeda does not believe the concerns about a monopoly will delay the deal.
3. The European Union is the last regulatory body Takeda needs to win over to clear the deal. The company’s shareholders still have to approve the deal.
4. Takeda’s $62 billion acquisition will make it one of the world’s largest and most indebted drug makers.
More articles on gastroenterology:
Dixie Regional Medical Center opens outpatient respiratory clinic — 3 notes
ASC supply chain tip of the day: Collaborate with sales reps
Drs. Richard Blumberg, Brent Lacey & more: 3 GI physicians making headlines
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.